Welcome to our dedicated page for Immatics N.V SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immatics N.V. (IMTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ. Immatics files annual reports under Form 20‑F and furnishes current information on Form 6‑K, giving investors structured insight into its clinical programs, collaborations and financial position.
Recent Form 6‑K reports describe interim financial results, business updates and detailed clinical data for Immatics’ PRAME‑focused pipeline. These filings include summaries of Phase 1a and 1b trials for the second‑generation PRAME cell therapy IMA203CD8 in solid tumors, the IMA402 PRAME TCR Bispecific, and the IMA401 MAGEA4/8 TCR Bispecific, along with information on tolerability, response rates, disease control and progression‑free survival in heavily pretreated patient populations. Other 6‑K submissions incorporate interim reports for quarterly periods, outlining revenue from collaboration agreements, research and development expenses, cash position and changes in share capital.
On this page, users can review Immatics’ furnished reports to understand how the company characterizes its PRAME franchise, its TCR Bispecific (TCER®) platform and its strategic collaborations with partners such as Moderna, Bristol Myers Squibb and Genmab. The filings also document corporate developments, including leadership appointments and pipeline prioritization decisions.
Stock Titan enhances these filings with AI‑powered summaries that highlight key clinical and financial points from lengthy documents, helping readers quickly identify material updates. Real‑time ingestion from EDGAR means new Immatics 6‑K and 20‑F submissions appear promptly, and investors can also monitor incorporated exhibits such as press releases and investor presentations referenced in the filings.
RTW Investments, LP and Roderick Wong, M.D. report beneficial ownership of 11,433,354 ordinary shares of Immatics N.V., representing 8.5% of the company’s outstanding shares. The shares are held by funds advised by RTW Investments, and both RTW and Dr. Wong share voting and dispositive power over them.
The ownership percentage is based on 134,063,829 Immatics ordinary shares outstanding as of December 8, 2025. The filers state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Immatics.
Immatics N.V. received an updated ownership report showing that investment adviser Suvretta Capital Management, LLC and its related entities hold a significant stake in the company’s ordinary shares, nominal value €0.01 per share, as of December 31, 2025.
Suvretta Capital Management, LLC and Aaron Cowen each report beneficial ownership of 11,190,129 Immatics ordinary shares, representing 8.3% of the class, all with shared voting and dispositive power. Averill Master Fund, Ltd. reports 9,545,798 shares, or 7.1% of the class. All securities are directly owned by advisory clients of Suvretta, and the filers state the holdings are not intended to change or influence control of Immatics.
Immatics N.V. has released an updated investor presentation highlighting progress across its PRAME-targeted oncology franchise and related bispecific programs. The company positions itself as a leader in PRAME targeting, with three clinical product candidates: the autologous TCR cell therapy anzu-cel (IMA203), next-generation cell therapy IMA203CD8, and bispecific T cell engager IMA402, plus the MAGEA4/8 bispecific IMA401 for potential combinations.
In advanced melanoma, anzu-cel showed a confirmed objective response rate of 56% (18/32) and a median duration of response of 12.1 months, with median progression-free survival of 6.1 months and median overall survival of 15.9 months in heavily pretreated patients. A randomized phase 3 trial in unresectable or metastatic melanoma post checkpoint inhibitor and a phase 2 uveal melanoma cohort are ongoing, with a launch targeted in 2027 if development is successful.
IMA203CD8 is in phase 1 dose escalation across multiple PRAME-positive solid tumors, showing a 46% overall response rate and deep, durable responses at a median dose of 1.6 billion TCR T cells, while IMA402 has completed phase 1a dose escalation with a 30% confirmed response rate at doses within the proposed 10–30 mg range. Immatics estimates more than 230,000 PRAME+/HLA-A*02:01+ patients per year in the US and EU5 could be addressable across waves of cell and bispecific therapies.
Immatics reported updated Phase 1a data for its second-generation PRAME-targeted cell therapy IMA203CD8 in heavily pre-treated patients with advanced solid tumors as of October 27, 2025.
The one-time infusion showed promising anti-tumor activity, including three complete responses and two confirmed partial responses with 100% reduction of target lesions, with deep and durable responses seen for up to more than three years and seven still ongoing for at least one year.
Safety was described as manageable, with mostly expected cytopenias from lymphodepletion, cytokine release syndrome, infrequent neurotoxicity and hemophagocytic lymphohistiocytosis, and no Grade 5 events judged related to IMA203CD8.
In ovarian carcinoma, two of five patients treated at higher dose levels had confirmed partial responses in platinum-resistant disease without post-infusion low-dose IL-2, supporting plans to develop IMA203CD8 for PRAME-positive cancers beyond melanoma and to determine a recommended Phase 2 dose in 2026.
Immatics N.V., a clinical-stage biotech focused on PRAME-targeted cancer therapies, is conducting a public offering of its ordinary shares listed on Nasdaq as “IMTX.” The company intends to use the net proceeds to fund continued research and development across its PRAME pipeline, support manufacturing and potential commercialization of product candidates, and for working capital and general corporate purposes.
Immatics highlights updated Phase 1a data for its second-generation PRAME cell therapy IMA203CD8, showing a cORR of 36% (23/64), ORR of 46% (32/69) and median duration of response of 9.2 months at a 14‑month median follow-up. In a small ovarian carcinoma subgroup (N=5) at higher dose levels, two patients had confirmed partial responses and one had an unconfirmed partial response. As of September 30, 2025, cash and cash equivalents were €334.9 million and total shareholders’ equity was €416.7 million, providing a substantial capital base ahead of this raise.
Immatics N.V. (IMTX) submitted a Form 6-K to provide investors with an interim report for the three- and nine-month period ended September 30, 2025 and a related press release with its third quarter 2025 financial results and business update. The interim report is furnished as Exhibit 99.1 and the press release as Exhibit 99.2.
The interim report and Exhibit 99.1 are also incorporated by reference into Immatics' existing Form S-8 and Form F-3 registration statements, meaning those registration statements now include the updated information from this interim report.
Immatics N.V. (IMTX) reported updated early‑stage clinical results for its bispecific TCR candidates and outlined next steps. In Phase 1a, IMA402 (PRAME) treated 80 heavily pre‑treated patients across doses from 0.02–30 mg. A provisional RP2D range of 10–30 mg was identified; the MTD was not reached, and tolerability was favorable with low‑grade CRS (Grade 1
Within the RP2D range, 20 efficacy‑evaluable patients showed a confirmed objective response rate of
IMA401 (MAGEA4/8) enrolled 55 patients across 0.0066–2.5 mg, establishing a provisional RP2D of 1–2 mg with low‑grade CRS (24% G1, 11% G2), no ≥Grade 3 CRS and no ICANS; three dose‑limiting events occurred at 2.5 mg. A longest confirmed response exceeded two years. The company is advancing IMA402 to Phase 1b (monotherapy and checkpoint inhibitor combinations) and exploring IMA401+IMA402 combinations in sqNSCLC; it also deprioritized IMA204 and ACTallo.
Immatics N.V. appointed Amie Krause as chief people officer, effective October 27, 2025. Krause brings more than 20 years of experience aligning talent and strategy at global biopharmaceutical companies. She previously held senior HR leadership roles at Dompé, Revance Therapeutics, Atara Biotherapeutics, and spent over a decade at Amgen across multiple regions.
The company issued a press release attached as Exhibit 99.1. This report (excluding Exhibit 99.1) is incorporated by reference into Immatics’ Form S-8 and Form F-3 registration statements.
Immatics N.V. has appointed Venkat Ramanan as its chief financial officer, effective October 1, 2025. He brings more than 25 years of experience in finance, strategy and operations across large and small biopharmaceutical companies.
Ramanan previously served as chief financial officer at Anthos Therapeutics, a clinical-stage biotechnology company acquired by Novartis in April 2025, and at Turnstone Biologics, where he helped lead its initial public offering. He also held senior finance roles at Seagen, Gilead Sciences and Amgen, and holds a Ph.D. in Engineering Mechanics from The Ohio State University. Immatics issued a press release with further details, attached as an exhibit.
Baker Bros. Advisors and affiliated persons report beneficial ownership of 10,168,901 ordinary shares of Immatics N.V., representing 8.4% of the company’s outstanding common stock based on 121,550,169 shares outstanding as reported in the issuer's public filing. The reported holdings are held by two funds (Life Sciences and 667) for which the adviser has sole voting and dispositive power, with 9,354,564 shares held by Life Sciences and 814,337 shares held by 667. This filing amends prior Schedule 13G disclosures and clarifies ownership and control relationships among the adviser, its GP and two individual reporting persons.